Results 121 to 130 of about 195,437 (284)

"Colomycin" Treatment of Klebsiella Aerogenes Infection of Urinary Tract in Paraplegia [PDF]

, 1963
E. W. Colley, H L Frankel
openalex   +1 more source

Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity

Clinical Pharmacology &Therapeutics, EarlyView.
Polymyxins are used against highly resistant Gram‐negative pathogens, and nephrotoxicity (acute kidney injury, AKI) is the major dose‐limiting adverse effect. We aimed to develop a well‐informed population pharmacokinetic/toxicodynamic (PK/TD) model using the largest polymyxin B‐treated critically ill patient population studied to inform polymyxin B ...
Patrick O. Hanafin, Ramya Mahadevan, Gauri G. Rao, Alexandre P. Zavascki, Ana Maria Sandri, Andrea Kwa, Marc H. Scheetz, Christine J. Kubin, Jayesh Shah, Benjamin P.Z. Cherng, Michael T. Yin, Jiping Wang, Lu Wang, David P. Calfee, Maureen Bolon, Anthony W. Purcell, Roger L. Nation, Jason M. Pogue, Jian Li, Keith S. Kaye   +19 more
wiley   +1 more source

Experience with Nalidixic Acid in the Treatment of Urinary Tract Infections of Children [PDF]

, 1966
S. Autio, Petra Mäkelä, R Sunila
openalex   +1 more source

Spotlight commentary: Treatment of multidrug‐resistant Gram‐negative infections in the era of growing antimicrobial resistance

British Journal of Clinical Pharmacology, EarlyView.
Luka Bielen, Andro Vujević, Luka Csenar
wiley   +1 more source

The Spectrum of Polyoma Virus and Polyoma Virus‐Like Changes in Urine Cytology: When Should an Atypical Diagnosis Be Considered

Diagnostic Cytopathology, EarlyView.
ABSTRACT Background While the Paris system for reporting urinary cytology states that cells with well‐recognized and typical changes of polyoma virus (PV) infection should not lead to a diagnosis of ‘atypia, the prognostic significance of PV‐like features is unknown. Methods Included were 284 urine cytology cases with PV or PV‐like changes.
Yaogong Li, Yonca Kanber, Derin Caglar, Wassim Kassouf, Manon Auger, Fadi Brimo   +5 more
wiley   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

URINARY-TRACT INFECTION

The Lancet, 1974
openaire   +4 more sources

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

In Vitro Efficacy Of Fosfomycin Against Various Urinary Isolates

Gomal Journal of Medical Sciences, 2013
Background: Urinary tract infections are one of the most common infections especially in young adults and pregnant women. Due to increase in fluoroquinolones use, empirical therapy in uncomplicated urinary tract infections with this group is now ...
Viqar Ashraf, Luqman Satti, Muhammad Altaf, M Uzair Ilyas Tahirkheli   +3 more
doaj  

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
wiley   +1 more source